Tirzepatide is one molecule sold under two brand names by one company. Eli Lilly markets it as Zepbound for weight management and as Mounjaro for type 2 diabetes, and there is no third seller, because no generic version exists anywhere in the United States.
That means shopping for tirzepatide is not shopping for the drug, it is shopping for the route. This guide prices every route a cash payer can legally take in August 2026, converts each one to cost per milligram so you can compare them honestly, and explains where compounded tirzepatide stands after the FDA ended the shortage. All figures were verified on Lilly’s, FDA’s, and SingleCare’s own pages on August 31, 2026.
What Does Tirzepatide Cost Without Insurance?
The monthly spread across legal routes is roughly $299 to $1,519, and almost all of that gap is channel, not chemistry.
| Route | Low | Average | High |
|---|---|---|---|
| Zepbound self-pay, LillyDirect (vial or KwikPen) | $299/mo | $449/mo | $699/mo |
| Mounjaro self-pay, LillyDirect (pen) | $499/mo | $499/mo | $499/mo |
| Retail pharmacy counter with a discount card | $490/mo | $650/mo | $872/mo |
| Retail pharmacy counter, no card | $655/mo | $1,112/mo | $1,519/mo |
| Compounded tirzepatide | no longer a broadly legal route | see below | see below |
Zepbound and Mounjaro self-pay prices come from Lilly’s own LillyDirect product pages. The retail rows use SingleCare’s live Zepbound and Mounjaro pages plus Lilly’s published list prices. The compounded row is deliberately empty, and the reason is below.
Route 1: Zepbound self-pay through LillyDirect
Zepbound is the cheapest branded tirzepatide, and Lilly sells it in three formats. As of August 2026 the LillyDirect Zepbound page lists self-pay prices of $299 per month for the 2.5 mg starting dose, $399 for 5 mg, and $449 for 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Those prices apply to both the single-dose vial (four vials per 28-day month) and the single-patient-use KwikPen (one pen per 28-day month).
The $449 price on the four highest doses is conditional. Lilly’s terms state it reflects the Zepbound Journey Program, and that regular prices apply if you do not refill within 45 days: $499 for 7.5 mg and $699 for 10 mg, 12.5 mg, and 15 mg. Lilly’s pricing page lists that unconditioned self-pay ladder as $299, $399, $499, $699, $699, and $699 across the six doses.
Route 2: Mounjaro self-pay through LillyDirect
Mounjaro’s self-pay price is a flat $499 per month at every dose from 2.5 mg through 15 mg, on the single-dose prefilled pen, with a month defined as 28 days and four pens. There is no self-pay vial. See our Mounjaro cost guide for the savings-card tiers and list price detail.
You do not get to pick between these two prices. Zepbound and Mounjaro are approved for different conditions, so the indication your prescriber writes determines which program you can use.
Route 3: the pharmacy counter
Paying cash at an ordinary pharmacy is the expensive route, and the numbers are worth seeing. SingleCare’s Zepbound page currently shows an average retail price of $655.33 for one 2.4 mL KwikPen at the 2.5 mg dose, discounted to $490.02 with its free coupon. On Mounjaro, SingleCare shows $1,519.20 average retail for four 5 mg pens, discounted to $872.48.
So even the best counter price on the starting dose costs about $191 a month more than buying that same starting dose direct from Lilly at $299. Discount cards do real work on most drugs, but on brand tirzepatide they cannot beat the manufacturer. Our GoodRx vs. SingleCare guide explains where cards do and do not win.
Route 4: compounded tirzepatide, and what changed
During the 2022 to 2024 shortage, compounding pharmacies and telehealth sellers could lawfully make and sell copies of tirzepatide, and prices well under branded levels were common. That legal basis is gone.
FDA determined the tirzepatide injection shortage was resolved on December 19, 2024. The agency then gave compounders a wind-down window: enforcement discretion ended February 18, 2025 for state-licensed pharmacies and physicians compounding under section 503A, and March 19, 2025 for outsourcing facilities under section 503B, after a federal court declined to block the decision.
FDA’s current guidance, updated April 1, 2026, states plainly that tirzepatide and semaglutide appear on neither the 503B bulks list nor the drug shortage list. On April 30, 2026 the agency went further and proposed formally excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound them from bulk substances, with a comment docket that closed June 29, 2026.
Two narrow paths remain, and it is worth being precise rather than alarmist about them. A 503A compounder can still prepare a patient-specific product when a prescriber determines and documents that a change produces a significant difference from the commercially available drug for that individual patient. Separately, FDA has said it does not intend to act against a compounder that fills four or fewer prescriptions of a given essentially-a-copy product in a calendar month. Neither of those supports a mass-market subscription offering, which is why the large telehealth tirzepatide programs of 2024 no longer look the way they did. This site does not recommend or price any specific compounder.
What Drives the Price
Brand and indication. The same molecule is $299 to $449 as Zepbound and $499 as Mounjaro. Nothing about the chemistry explains that, only the program.
Dose, in a nonlinear way. Because Lilly caps its Zepbound self-pay price at $449 and its Mounjaro price at $499 regardless of strength, the cost per milligram falls sharply as you titrate up. Here is the math on the Zepbound self-pay ladder, at four doses per 28-day month:
| Dose | mg per month | Zepbound self-pay | Cost per mg |
|---|---|---|---|
| 2.5 mg | 10 mg | $299 | about $29.90 |
| 5 mg | 20 mg | $399 | about $19.95 |
| 7.5 mg | 30 mg | $449 | about $14.97 |
| 15 mg | 60 mg | $449 | about $7.48 |
Mounjaro’s flat $499 runs about $49.90 per mg at 2.5 mg and about $8.32 per mg at 15 mg. At Mounjaro’s $1,112.16 list price, the same 15 mg month costs about $18.54 per mg.
Refill timing. On Zepbound’s four highest doses, missing the 45-day refill window moves you from $449 to $499 or $699. That is a $250 monthly swing driven purely by a calendar.
Channel. Manufacturer-direct beats the counter by $191 to $620 a month depending on brand and dose.
No competition. FDA’s Orange Book lists tirzepatide drug substance and drug product patents on both Zepbound and Mounjaro expiring May 13, 2036, with follow-on patents running to June 2039, July 2039, and December 30, 2041. New chemical entity exclusivity on both runs through May 13, 2027. There is no approved generic and no realistic near-term path to one, so prices move only when Lilly moves them.
Cash Price vs. Insurance
Insurance beats cash on tirzepatide only when the plan actually covers it. Commercially insured patients with coverage can pay as little as $25 a month through Lilly’s savings cards on either brand. That is the best outcome available, full stop.
The trouble is that many commercial plans exclude weight-management drugs outright, and Medicare and Medicaid patients are barred from manufacturer savings cards entirely. In both cases the self-pay ladder is not a fallback, it is your real price, and it is open to anyone regardless of insurance status.
If you are on a high-deductible plan, compare carefully. A $299 to $499 monthly cash price is often lower than the pre-deductible price your plan would apply, and cash purchases are simpler to budget. The trade-off is that self-pay spending does not count toward your deductible or out-of-pocket maximum. Our fair price checker is a quick sanity check on the surrounding costs, like the office visit needed to get the prescription.
How to Pay Less
-
Buy manufacturer-direct, every time. LillyDirect is the floor for both brands. No card, coupon, or pharmacy has beaten it in 2026.
-
Protect the 45-day refill window on Zepbound maintenance doses. Set a calendar reminder. It is worth $250 a month at 10 mg and above.
-
Ask about format, not just dose. Zepbound self-pay prices are identical for the vial and the KwikPen, so the choice is about handling preference and needle costs rather than price. Vials require a syringe and needle purchase, KwikPens require pen needles.
-
Do not chase a generic that does not exist. Anything sold as generic tirzepatide is compounded, not FDA-approved, and after the 2025 wind-down the legal basis for mass-market copies is gone. Price the branded routes instead.
-
Handle the visit costs separately. A prescription is required and follow-up is ongoing. A free or sliding-scale clinic can cover the prescribing visit cheaply, and if a bill from that care turns into a problem, negotiating medical bills is a real option.
-
Recheck before every refill. Lilly has cut and restructured self-pay tiers more than once since 2024, and FDA’s compounding posture is still moving.
Bottom Line
In August 2026 the honest answer to “what does tirzepatide cost” is $299 to $499 a month if you buy the brand direct from Lilly, and $490 to $1,519 if you buy it anywhere else without a program. The molecule has no generic, no legal discount channel outside the manufacturer, and no third supplier.
If you are comparing across the whole class rather than sticking with tirzepatide, our GLP-1 cost guide lays out every brand’s self-pay program side by side, including the semaglutide products from Novo Nordisk.